Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lumiracoxib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 11/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 4/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | NR1I3 | Q14994 | 2/20 | 1.00 |
| ▸ | PPARG | P37231 | 1/20 | 1.00 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 0.63 |
| ▸ | TTR | P02766 | 2/20 | 0.56 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.56 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.56 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.56 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.56 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.56 |
| ▸ | ALB | P02768 | 1/20 | 0.56 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.56 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.56 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.56 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lumiracoxib SCHEMBL29475008 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1ABCB11NR1I3PPARG | |
| Lumiracoxib SCHEMBL4479 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1ABCB11NR1I3PPARG | |
| Lumiracoxib SCHEMBL27680523 | 0.99 | PTGS2 (0.98) | PTGS2PTGS1ABCB11NR1I3PPARG | |
| Lumiracoxib SCHEMBL6063194 | 0.93 | PTGS2 (0.87) | PTGS2PTGS1ABCB11NR1I3PPARG | |
| SCHEMBL1031733 | 0.91 | PTGS2 (1.00) | PTGS2PTGS1ABCB11NR1I3PPARG | |
| SCHEMBL17917294 | 0.91 | PTGS2 (0.85) | PTGS2PTGS1ABCB11NR1I3PPARG | |
| SCHEMBL5533958 | 0.90 | PTGS2 (0.82) | PTGS2PTGS1ABCB11NR1I3PPARG | |
| SCHEMBL3120262 | 0.90 | PTGS2 (0.82) | PTGS2PTGS1ABCB11NR1I3PPARG | |
| SCHEMBL17208147 | 0.88 | PTGS2 (0.79) | PTGS2PTGS1ABCB11NR1I3PPARG | |
| SCHEMBL5534966 | 0.88 | PTGS2 (0.79) | PTGS2PTGS1ABCB11NR1I3PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3713918-B1 | SULFASALAZINE SALTS, PRODUCTION PROCESSES AND USES | MEDAC GES FUER KLINISCHE SPEZIALPRAEPARATE MBH (DE) | 2025-07-23 | — | — | EP | claimed |
| US-12274706-B2 | Pharmaceutical composition for oral administration containing sulfasalazine and/or a sulfasalazine organic salt, production process and use | MEDAC GESELLSCHAFT FUER KLINISCHE (DE) | 2025-04-15 | — | — | US | claimed |
| EP-4509496-A2 | SULFASALAZINE SALTS, PRODUCTION PROCESSES AND USES | medac Gesellschaft für klinische Spezialpräparate mbH (DE) | 2025-02-19 | — | — | EP | claimed |
| US-20240423966-A1 | SULFASALAZINE SALTS, PRODUCTION PROCESSES AND USES | MEDAC GES FUER KLINISCHE SPEZIALPRAEPARATE MBH (DE) | 2024-12-26 | — | — | US | claimed |
| US-11883405-B2 | Pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy | AMPLIO PHARMA AB (SE) | 2024-01-30 | — | — | US | claimed |
| US-20230381203-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION CONTAINING SULFASALAZINE AND/OR A SULFASALAZINE ORGANINC SALT, PRODUCTION PROCESS AND USE | MEDAC GES FUER KLINISCHE SPEZIALPRAEPARATE MBH (DE) | 2023-11-30 | — | — | US | claimed |
| EP-3488868-B1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION CONTAINING SULFASALAZINE AND / OR A SULFASALAZINE ORGANIC SALT, PRODUCTION PROCESS AND USE | MEDAC GES FUER KLINISCHE SPEZIALPRAEPARATE MBH (DE) | 2023-09-13 | — | — | EP | claimed |
| US-20230064978-A1 | CYCLIC PEPTIDE RECEPTOR LANTHIONINE SYNTHETASE C-LIKE PROTEIN (LANCL) AND USES THEREOF | Lateral IP Pty Ltd (AU) | 2023-03-02 | — | — | US | claimed |
| EP-4081237-A1 | CYCLIC PEPTIDE RECEPTOR LANTHIONINE SYNTHETASE C-LIKE PROTEIN (LANCL) AND USES THEREOF | LATERAL IP PTY LTD (AU) | 2022-11-02 | — | — | EP | claimed |
| US-20220313667-A1 | SULFASALAZINE SALTS, PRODUCTION PROCESSES AND USES | MEDAC GES FUER KLINISCHE SPEZIALPRAEPARATE MBH (DE) | 2022-10-06 | — | — | US | claimed |
| EP-3998932-A1 | ALKALIZATION OF URINARY BLADDER WALL PRIOR TO TREATMENT WITH INTRAVESICAL HEPARIN AND ALKALINIZED LIDOCAINE TO ENHANCE RELIEF OF BLADDER PAIN SYMPTOMS | Parsons, C. Lowell (US) | 2022-05-25 | — | — | EP | claimed |
| US-11304936-B2 | Sulfasalazine salts, production processes and uses | MEDAC GESELLSCHAFT FUER KLINISCHE SPEZIALPRAEPARATE MBH | 2022-04-19 | — | — | US | claimed |
| US-12612631-B2 | Small RNA medicament for prevention and treatment of inflammation-related diseases and combination thereof | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2026-04-28 | — | — | US | disclosed |
| US-20260092050-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-12491207-B2 | Article of manufacture comprising local anesthetic, buffer, and glycosaminoglycan in syringe with improved stability | VANELTIX PHARMA, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-11304936-B2 | Sulfasalazine salts, production processes and uses | MEDAC GESELLSCHAFT FUER KLINISCHE SPEZIALPRAEPARATE MBH | 2022-04-19 | — | — | US | disclosed |
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | PALATIN TECHNOLOGIES, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| EP-3960858-A1 | SMALL RNA MEDICAMENT FOR PREVENTION AND TREATMENT OF INFLAMMATION-RELATED DISEASES AND COMBINATION THEREOF | Institute of Basic Medical Sciences Chinese Academy of Medical Sciences (CN) | 2022-03-02 | — | — | EP | disclosed |
| US-11234955-B2 | Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multiforme and medulloblastoma | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | PTGS2 2948/4885PTGS1 3442/4885ABCB11 1392/4885 |
| US-12491207-B2 | Article of manufacture comprising local anesthetic, buffer, and glycosaminoglycan in syringe with improved stability | OGFR, ALOX5, PTGS1 | PTGS2 21/4885PTGS1 3/4885ABCB11 2680/4885 |
| US-12612631-B2 | Small RNA medicament for prevention and treatment of inflammation-related diseases and combination thereof | EIF2AK2, IL1A, IRF3 | PTGS2 538/4885PTGS1 233/4885ABCB11 2944/4885 |
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | MC3R, MC1R, MC2R | PTGS2 1258/4885PTGS1 539/4885ABCB11 4008/4885 |
| US-20230381203-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION CONTAINING SULFASALAZINE AND/OR A SULFASALAZINE ORGANINC SALT, PRODUCTION PROCESS AND USE | SI, ALPI, SOST | PTGS2 877/4885PTGS1 483/4885ABCB11 334/4885 |
| US-20260092050-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | CCR1, CXCR2, CCR2 | PTGS2 3305/4885PTGS1 1474/4885ABCB11 891/4885 |
| US-11304936-B2 | Sulfasalazine salts, production processes and uses | TPMT, SI, IL5 | PTGS2 464/4885PTGS1 266/4885ABCB11 795/4885 |
| US-20240423966-A1 | SULFASALAZINE SALTS, PRODUCTION PROCESSES AND USES | SI, TPMT, MGAM | PTGS2 503/4885PTGS1 296/4885ABCB11 1166/4885 |
| US-11234955-B2 | Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multiforme and medulloblastoma | MGMT, MPG, HDAC7 | PTGS2 1668/4885PTGS1 1040/4885ABCB11 3946/4885 |
| US-20220313667-A1 | SULFASALAZINE SALTS, PRODUCTION PROCESSES AND USES | SI, TPMT, MGAM | PTGS2 503/4885PTGS1 296/4885ABCB11 1166/4885 |
| US-11883405-B2 | Pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy | MTX1, MTX2, SSB | PTGS2 2189/4885PTGS1 1891/4885ABCB11 16/4885 |
| US-12274706-B2 | Pharmaceutical composition for oral administration containing sulfasalazine and/or a sulfasalazine organic salt, production process and use | SI, SOST, SLC10A2 | PTGS2 202/4885PTGS1 303/4885ABCB11 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.